Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Osteopore gets CE mark extension, significantly increases market access in Europe
News
Quarterlies recap: Here are five Q1 updates you may have missed this afternoon
Health & Biotech
Osteopore pockets European patent for its ‘smart’ 3D scaffolds, sets eyes on expansion in the continent
Stockhead TV
3D printing – huge growth potential, new applications and a massive addressable market
Health & Biotech
Altor Capital has high conviction on these 4 medtech plays for 2021
Health & Biotech
Broken bones are no pretty picture but these ASX stocks help you diagnose or fix them
Health & Biotech
Why 3D printing represents a medical revolution in orthopaedics
Health & Biotech
Osteopore inks partnership with US blood technology company
News
Tech space has its day in Perth sun
Health & Biotech
Health Kick Podcast: Osteopore’s expansion plans and new markets after 2019’s stellar IPO
Health & Biotech
Osteopore inks first ANZ distribution deal, adds ex-ResMed exec
Health & Biotech
Osteopore to work with Singapore medical school on 3D printed jaws
Health & Biotech
Osteopore attracts $8.5m from top-tier instos to expand its bone healing tech horizons
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV
StockTalk: How are ASX medtechs responding to skyrocketing healthcare spending?
Health & Biotech